Article discusses a model developed which may help predict patient’s tolerability to receive chemoimmunotherapy in DLBCL.
Home / Resource Library / TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma